Novo Nordisk’s Amycretin Shows Strong Phase 2 Diabetes Results
Bagsværd, Denmark, Nov. 25, 2025 — Novo Nordisk has announced positive Phase 2 clinical trial results for amycretin, a...
Novo Nordisk
Advertisement
Novo Nordisk Reshapes Leadership Structure Following EGM Vote
Dateline: November 14, 2025 — Bagsværd, DenmarkNovo Nordisk A/S announced a series of major Board of Directors changes following...
Emcure Partners with Novo Nordisk to Bring Semaglutide to India
Bengaluru, November 10, 2025 — Global diabetes-care leader Novo Nordisk India has entered into a strategic partnership with Emcure...
Pfizer Challenges Novo Nordisk’s Proposal to Acquire Metsera
New York, October 30, 2025 — Pfizer Inc. (NYSE: PFE) has issued a strong response to what it calls...
Novo Nordisk: Ozempic® Cuts Mortality and CV Events in Real-World Study
Bagsværd, Denmark – September 18, 2025 – Novo Nordisk A/S announced landmark results from the REACH real-world study showing...
Advertisement
